Advertisement
Advertisement
U.S. markets open in 2 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Pulmonx Corporation (LUNG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.71+2.38 (+14.57%)
At close: 04:00PM EDT
18.71 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close16.33
Open16.84
Bid0.00 x 2200
Ask0.00 x 1300
Day's Range16.72 - 18.72
52 Week Range15.06 - 45.81
Volume446,327
Avg. Volume506,270
Market Cap694.452M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.35
Earnings DateAug 01, 2022 - Aug 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.43
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LUNG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pulmonx Corporation
    Daily – Vickers Top Buyers & Sellers for 05/10/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Motley Fool

    Pulmonx Corporation (LUNG) Q1 2022 Earnings Call Transcript

    Joining me from Pulmonx are Glendon French, president and chief executive officer; and Derrick Sung, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.

  • Zacks

    Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

    Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of -16.22% and 14.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Pulmonx Reports First Quarter 2022 Financial Results

    REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Recorded worldwide revenue of $10.8 million in the first quarter of 2022, a 17% increase over the same period last year and an increase of 20% on a constant currency basisRealized gross margin of 75% in the first quart

Advertisement
Advertisement